- The University of Sheffield with Sheffield Teaching Hospitals NHS Foundation Trust is the only site in the UK to have participated in an international clinical trial for an investigational drug in people with a form of motor neurone disease (MND)
- Results from Phase 1-2 of the study sponsored by biotechnology company Biogen Inc. was published in the New England Journal of Medicine
- About 5,000 people in the UK have MND – also known as amyotrophic lateral sclerosis (ALS), with two per cent developing MND due to a faulty gene called SOD1
- The disease affects motor neurons in the brain and spinal cord and progressively affects the ability to walk, talk, eat and breathe
Results from Phase 1-2 of a study published in the New England Journal of Medicine, have shown the safety and tolerability of the new investigational drug tofersen which shows the potential to reduce the levels of a toxic cell protein in people living with a form of motor neurone disease (MND); triggered by a faulty gene called SOD1 which causes the progression of the disease.
SOD1 is the known cause for triggering MND in two per cent of all patients with ALS, and up to 20 per cent of patients who have a family history of the disease.
Scientists from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) worked with the Sheffield Teaching Hospitals NHS Foundation Trust on the study at the National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre, the only site in the UK to participate in this exciting international clinical trial which evaluated the safety and efficacy of the investigational drug developed for SOD1 MND.
Amyotrophic lateral sclerosis (ALS), or motor neurone disease as is it known in the UK, is a disorder that affects the nerves - or motor neurons - in the brain and spinal cord that form the connection between the nervous system and muscles to enable movement of the body. The messages from these nerves gradually stop reaching the muscles, leading them to weaken, stiffen and eventually waste. The progressive disease affects a patient’s ability to walk, talk, use their arms and hands, eat and breathe.
I’m one of three siblings who all inherited the SOD1 gene and was in my mid-50s when I started noticing symptoms. My sisters had both developed MND earlier and I saw how quickly their condition deteriorated. So the research into diseases like MND that is happening now is so important.
Les Wood
66, from Doncaster has been living with MND since 2012
The rise of genetic screening in our clinic means that we can now identify the different genetic subtypes of MND, which is helping to enhance the research effort.
“It has been a real privilege to participate in this trial of the investigational drug tofersen here in Sheffield, and our patients have shown huge commitment in taking part; so it’s a step forward that the published results warrant additional study in a larger patient group.”
Professor Dame Pamela Shaw
Director of SITraN, European Chief Investigator on the trial and Director of the NIHR Sheffield Biomedical Research Centre
Superoxide dismutase 1, known as SOD1 was the first gene found to cause MND. It is an enzyme found in all living cells that acts as an antioxidant to reduce reactive oxygen species that would otherwise cause damage. About 2 per cent of people with MND have this mutation which causes the enzyme itself to be toxic to their cells.
“The primary objective of the study was to evaluate the safety and tolerability of tofersen which shows signs of potential efficacy in lowering the levels of the toxic SOD1 protein in the nervous system, something which will reduce damage in the nerve cells and help to slow the progression of symptoms."
Professor Chris McDermott
from SITraN, Principal Investigator of the Sheffield trial and NIHR Sheffield BRC Deputy Director
The study also makes clear the reported adverse events, or apparent side effects, experienced by some of the participants such as headache, procedural pain, post-lumbar puncture syndrome and falls. Five tofersen, and two placebo-treated participants experienced serious adverse events. One death occurred in the placebo group during the trial due to respiratory failure secondary to MND and two deaths occurred in the tofersen group during a follow up period due to pulmonary embolism and respiratory failure. The next phase of the trial will continue to further explore the safety and efficacy of the investigational drug.
It is a testimony to the research conducted at SITraN that Sheffield was the only UK site for the initial phases of the clinical trial. We look forward to the next stage of this clinical study sponsored by Biogen Inc. which will further evaluate the safety and efficacy of torfersen.”
Helen Wollff
Research Nurse on the Sheffield study based at SITraN
Media contact: Rebecca Ferguson, Media Relations Officer, 0114 222 9859 or r.l.ferguson@sheffield.ac.uk